Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an announcement.
Neuren Pharmaceuticals will host an investor webinar on 12 February 2026 to discuss recently announced business updates, offering investors an opportunity to engage directly with management and submit questions. The event underlines the company’s active communication with the market as it advances its approved Rett syndrome therapy DAYBUE and progresses NNZ-2591 through late-stage trials in rare neurodevelopmental disorders, potentially strengthening its position in the niche paediatric neurology space and enhancing long-term value for stakeholders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$27.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing novel drug therapies for serious neurological and neurodevelopmental disorders that emerge in early childhood and have limited or no approved treatment options. Its lead product trofinetide, marketed in the U.S. as DAYBUE and DAYBUE STIX for Rett syndrome, is licensed globally to Acadia Pharmaceuticals Inc., while its second candidate NNZ-2591 targets multiple rare neurodevelopmental syndromes and has received orphan drug designation in both the United States and European Union.
Average Trading Volume: 354,351
Technical Sentiment Signal: Sell
Current Market Cap: A$1.59B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.